Clinical trial NCT00477464: Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
Official title: Clinical Evaluation of Lapatinib Administered With Capecitabine in Japanese Patients With ErbB2 Overexpressing Advanced or Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Breast Cancer
Neoplasms, Breast
Keywords: dual kinase inhibitor,
EGFR/ErbB1,
ErbB2-overexpressing,
GW572016,
advanced/metastatic breast cancer, Lapatinib,
HER-2/new,
pharmacokinetics
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-05-23
Enrollment: 51
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the safety and efficacy of lapatinib taken together with capecitabine in Japanese patients. The study will proceed in two phases; the first phase(Part1) will lead to an evaluation of the mainly tolerability as well as PK parameters. If there are no major safety concerns in Part 1, the study will move into the second phase (Part 2) to further evaluate the safety and clinical activity.


Eligibility criteria: Inclusion criteria:

* Subjects eligible for enrolment in the study must meet all of the following criteria:
* Patients who have consent to this study participation and signed into Informed consent form.
* Subjects must have histologically confirmed invasive breast cancer with stage IIIB, stage IIIC with T4 lesion, or stage IV disease.
* Documentation of ErbB2 overexpression \[IHC3+ or IHC2+ with FISH confirmation\] is required based on local laboratory.
* Subjects must have documented progressive advanced or metastatic breast cancer.
* Subjects must have refractory breast cancer defined as progression in the locally advanced or metastatic setting or relapse within 6 months of completing adjuvant therapy. Prior therapies must include, but are not limited to:
* Taxane containing regimen for at least 4 cycles or 2 cycles provided disease progression occurred while on taxane.
* Anthracycline containing regimen for at least 4 cycles or 2 cycles provided disease progression occurred while on anthracycline.
* Subjects who relapse \>6 months after completion of adjuvant anthracycline-containing chemotherapy, and for whom further anthracycline is not indicated, will be considered to have met the anthracycline prior exposure requirement.
* Taxanes and anthracyclines may have been administered concurrently or separately.
* Prior treatment with capecitabine is not permitted.
* Prior treatment must have contained trastuzumab alone or in combination with other chemotherapy for at least 6 weeks of standard doses in the adjuvant or advanced/metastatic setting.
* Subjects with hormone receptor positive tumors must have disease progression following hormonal therapy unless intolerant to hormonal therapy or hormonal therapy is not considered to be clinically appropriate.
* Subjects with stable CNS metastases (asymptomatic, and off systemic steroids and anticonvulsants for at least 3 months) are eligible.
* Measurable disease according to modified RECIST (Response Evaluation Criteria in Solid Tumors) (see Section 6.2, Efficacy p.49).
* Subjects must have archived tumor tissue available for biomarker assessment.
* Female subjects must be ≥20
* ECOG Performance Status of 0 or 1.
* Life expectancy of ≥12 weeks.
* Measurable lesions may be in the field of prior irradiation. However, there must be at least a 4-week period between the last radiation treatment and the baseline scan documenting disease status for the lesion to be measurable.
* Cardiac ejection fraction within the institutional range of normal as measured by ECHO (or MUGA if ECHO is not available). If no institutional range is available, cardiac ejection fraction must be ≥50%.
* Adequate hematologic value, hepatic and renal function as defined below. Hematologic ANC (absolute neutrophil count) ≥1.5×109/L Hemoglobin ≥9 g/dL Platelets ≥100× 109/L Hepatic Serum bilirubin ≤1.5×ULN

  * 2.5×ULN if subject has Gilbert's syndrome AST and ALT ≤5×ULN if documented liver metastases
  * 3×ULN without liver metastases Renal Serum creatinine Creatinine clearance\* ≤50 mL/min

    * Calculated by the Cockcroft and Gault Method

Exclusion criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

* Pregnant or lactating females.
* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. In addition, subjects with ulcerative colitis are excluded.
* History of other malignancy. Subjects who have been disease-free for at least 5 years or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
* Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anticancer therapy.
* Active or uncontrolled infection.
* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
* Known history of uncontrolled or symptomatic angina, arrhythmia or congestive heart failure.
* No prior anti-ErbB1/ErbB2 inhibitor for breast cancer other than trastuzumab.
* Known history or clinical evidence of leptomeningeal carcinomatosis.
* Concurrent anticancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than capecitabine.
* Bisphosphonates for the treatment of bone metastases should not be initiated following the first dose of study medication. Prophylactic use of bisphosphonate in subjects without bone disease is not permitted, except for prevention of osteoporosis.
* Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
* Participation in other studies or use of other investigational drugs during this study.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib or excipients of lapatinib.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to capecitabine, fluorouracil or any excipients.
* Known dihydropyrimidine dehydrogenase (DPD) deficiency.
* Patients who an investigator judges ineligible to this study in consideration of patient's safety (e.g., complications).

Primary outcomes:
measure: Clinical Benefit Response (Independent Reviewer-assessed)
timeFrame: Baseline, every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119)
Secondary outcomes:
measure: Time to Progression (Independent Reviewer-assessed)
timeFrame: Baseline, every 6 weeks until Week 24 and then every 12 weeks until disease progression or death due to breast cancer (up to Week 119)
measure: Progression-free Survival (PFS) (Independent Reviewer-assessed)
timeFrame: Baseline, every 6 weeks until Week 24 and then every 12 weeks until disease progression or death (up to Week 119)
measure: 6-Month Progression-free Survival (Independent Reviewer-assessed)
timeFrame: Baseline and then every 6 weeks until Month 6 (Week 24)
measure: Objective Response (Independent Reviewer-assessed)
timeFrame: Baseline every 6 weeks until Week 24 and then every 12 weeks until disease progression or death (up to Week 119)
measure: Overall Survival (Independent Reviewer-assessed)
timeFrame: Baseline and then followed every 4 weeks until death (up to Week 157.9) while on treatment. After treatment termination, followed every 12 weeks until death (up to Week 157.9)
measure: Time to Response (Independent Reviewer-assessed)
timeFrame: Baseline, every 6 weeks until Week 24 and then every 12 weeks until disease progression or death (up to Week 119)
measure: Duration of Response (Independent Reviewer-assessed)
timeFrame: Baseline, every 6 weeks until Week 24 and then every 12 weeks until disease progression or death (up to Week 119)
measure: Maximum Plasma Concentration (Cmax) of Lapatinib
timeFrame: Week 2
measure: Time to Maximum Plasma Concentration (Tmax) of Lapatinib
timeFrame: Week 2
measure: Terminal Elimination Half-life (t1/2) of Lapatinib
timeFrame: Week 2
measure: Area Under the Plasma Concentration-time Curve Within the Dosing Interval AUC0-tau of Lapatinib
timeFrame: Week 2
measure: Area Under the Plasma Concentration-time Curve From Zero to 24 Hours AUC0-24 of Lapatinib
timeFrame: Week 2
measure: Cmax of Capecitabine, 5'-Fluorouracil (5-FU), and Alpha-fluoro-beta-alanine (FBAL)
timeFrame: Week 2
measure: Tmax of Capecitabine, 5'-Fluorouracil (5-FU), and Alpha-fluoro-beta-alanine (FBAL)
timeFrame: Week 2
measure: t1/2 of Capecitabine, 5'-Fluorouracil (5-FU), and Alpha-fluoro-beta-alanine (FBAL)
timeFrame: Week 2
measure: AUC0-tau of Capecitabine, 5'-Fluorouracil (5-FU), and Alpha-fluoro-beta-alanine (FBAL)
timeFrame: Week 2
measure: Area Under the Plasma Concentration-time Curve From Zero to 12 Hours (AUC0-12) of Capecitabine, 5'-Fluorouracil (5-FU), and Alpha-fluoro-beta-alanine (FBAL)
timeFrame: Week 2
measure: Trough Concentration of Lapatinib
timeFrame: Week 2
measure: Trough Concentration of Capecitabine, 5-FU, and FBAL
timeFrame: Week 2
Other outcomes:
Locations:
city: Aichi
country: Japan
facility: GSK Investigational Site
city: Chiba
country: Japan
facility: GSK Investigational Site
city: Ehime
country: Japan
facility: GSK Investigational Site
city: Fukuoka
country: Japan
facility: GSK Investigational Site
city: Hokkaido
country: Japan
facility: GSK Investigational Site
city: Ibaraki
country: Japan
facility: GSK Investigational Site
city: Kagoshima
country: Japan
facility: GSK Investigational Site
city: Osaka
country: Japan
facility: GSK Investigational Site
city: Osaka
country: Japan
facility: GSK Investigational Site
city: Shizuoka
country: Japan
facility: GSK Investigational Site
city: Tochigi
country: Japan
facility: GSK Investigational Site
city: Tokyo
country: Japan
facility: GSK Investigational Site
city: Tokyo
country: Japan
facility: GSK Investigational Site
city: Tokyo
country: Japan
facility: GSK Investigational Site
city: Tokyo
country: Japan
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: